• HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Thursday, February 25, 2021
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
    • BIOENGINEERING
    • SCIENCE NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • FORUM
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Chemistry

Synthesis of potent antibiotic follows unusual chemical pathway

Bioengineer by Bioengineer
January 18, 2021
in Chemistry
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

IMAGE

Credit: Booker Lab, Penn State

UNIVERSITY PARK, Pa. — Images of a protein involved in creating a potent antibiotic reveal the unusual first steps of the antibiotic’s synthesis. The improved understanding of the chemistry behind this process, detailed in a new study led by Penn State chemists, could allow researchers to adapt this and similar compounds for use in human medicine.

“The antibiotic thiostrepton is very potent against Gram-positive pathogens and can even target certain breast cancer cells in culture,” said Squire Booker, a biochemist at Penn State and investigator with the Howard Hughes Medical Institute. “While it has been used topically in veterinary medicine, so far it has been ineffective in humans because it is poorly absorbed. We studied the first steps in thiostrepton’s biosynthesis in hopes of eventually being able to hijack certain processes and make analogs of the molecule that might have better medicinal properties. Importantly, this reaction is found in the biosynthesis of numerous other antibiotics, and so the work has the potential to be far reaching.”

The first step in thiostrepton’s synthesis involves a process called methylation. A molecular tag called methyl group, which is important in many biological processes, is added to a molecule of tryptophan, the reaction’s substrate. One of the major systems for methylating compounds that are not particularly reactive, like tryptophan, involves a class of enzymes called radical SAM proteins.

“Radical SAM proteins usually use an iron-sulfur cluster to cleave a molecule called S-adenosyl-L-methionine (SAM), producing a “free radical” or an unpaired electron that helps move the reaction forward,” said Hayley Knox, a graduate student in chemistry at Penn State and first author of the paper. “The one exception that we know about so far is the protein involved in the biosynthesis of thiostrepton, called TsrM. We wanted to understand why TsrM doesn’t do radical chemistry, so we used an imaging technique called X-ray crystallography to investigate its structure at several stages throughout its reaction.”

In all radical SAM proteins characterized to date, SAM binds directly to the iron-sulfur cluster, which helps to fragment the molecule to produce the free radical. However, the researchers found that the site where SAM would typically bind is blocked in TsrM.

“This is completely different from any other radical SAM protein,” said Booker. “Instead, the portion of SAM that binds to the cluster associates with the tryptophan substrate and plays a key role in the reaction, in what is called substrate-assisted catalysis.”

The researchers present their results in an article appearing Jan. 18 in the journal Nature Chemistry.

In solving the structure, the researchers were able to infer the chemical steps during the first part of thiostrepton’s biosynthesis, when tryptophan is methylated. In short, the methyl group from SAM transfers to a part of TsrM called cobalamin. Then, with the help of an additional SAM molecule, the methyl group transfers to tryptophan, regenerating free cobalamin and producing the methylated substrate, which is required for the next steps in synthesizing the antibiotic.

“Cobalamin is the strongest nucleophile in nature, which means it is highly reactive,” said Knox. “But the substrate tryptophan is weakly nucleophilic, so a big question is how cobalamin could ever be displaced. We found that an arginine residue sits under the cobalamin and destabilizes the methyl-cobalamin, allowing tryptophan to displace cobalamin and become methylated.”

Next the researchers plan to study other cobalamin-dependent radical SAM proteins to see if they operate in similar ways. Ultimately, they hope to find or create analogs of thiostrepton that can be used in human medicine.

“TsrM is clearly unique in terms of known cobalamin-dependent radical SAM proteins and radical SAM proteins in general,” said Booker. “But there are hundreds of thousands of unique sequences of radical SAM enzymes, and we still don’t know what most of them do. As we continue to study these proteins, we may be in store for many more surprises.”

###

Squire Booker is an Evan Pugh University Professor of Chemistry and of Biochemistry and Molecular Biology and Holder of the Eberly Distinguished Family Chair in Science at Penn State. In addition to Booker and Knox, the research team at Penn State includes graduate students at the time of the research Anthony Blaszczyk and Erica Schwalm; postdoctoral researcher Arnab Mukherjee; and Assistant Research Professor of Chemistry Bo Wang. The team also includes Percival Yang-Ting Chen and Catherine Drennan at the Massachusetts Institute of Technology and former Penn State graduate student Tyler Grove, now an assistant professor at Albert Einstein College of Medicine.

This research was supported by the National Institutes of Health, the Penn State Eberly College of Science, and the Howard Hughes Medical Institute.

Media Contact
Gail McCormick
[email protected]

Original Source

http://science.psu.edu/news/Booker1-2021

Related Journal Article

http://dx.doi.org/10.1038/s41589-020-00717-y

Tags: BiochemistryBiologyChemistry/Physics/Materials SciencesMedicine/Health
Share12Tweet8Share2ShareShareShare2

Related Posts

IMAGE

How SARS-CoV-2’s sugar-coated shield helps activate the virus

February 25, 2021
IMAGE

Antibodies recognize and attack different SARS-CoV-2 spike shapes

February 25, 2021

Scientists reveal details of antibodies that work against Zika virus

February 25, 2021

Scientists uncover new details of SARS-CoV-2 interactions with human cells

February 25, 2021

Leave a Reply Cancel reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

POPULAR NEWS

  • IMAGE

    Terahertz accelerates beyond 5G towards 6G

    637 shares
    Share 255 Tweet 159
  • People living with HIV face premature heart disease and barriers to care

    81 shares
    Share 32 Tweet 20
  • Global analysis suggests COVID-19 is seasonal

    37 shares
    Share 15 Tweet 9
  • HIV: an innovative therapeutic breakthrough to optimize the immune system

    35 shares
    Share 14 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Tags

GeneticsChemistry/Physics/Materials SciencesMaterialscancerPublic HealthBiologyEcology/EnvironmentClimate ChangeCell BiologyMedicine/HealthTechnology/Engineering/Computer ScienceInfectious/Emerging Diseases

Recent Posts

  • Health professional societies address critical care clinician burnout
  • A Canadian success story: world-first to treat Fabry disease with gene therapy
  • How SARS-CoV-2’s sugar-coated shield helps activate the virus
  • Antibodies recognize and attack different SARS-CoV-2 spike shapes
  • Contact Us

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

© 2019 Bioengineer.org - Biotechnology news by Science Magazine - Scienmag.

Welcome Back!

Login to your account below

Forgotten Password?

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In